Investor Relations

English Français

Latest News

Apr 2, 2024

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

View Press Release

Mar 26, 2024

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Feb 7, 2024

Medexus Announces Fiscal Q3 2024 Results

View All News

2024 Bloom Burton & Co. Healthcare Investor Conference

View Event Add to Calendar View All

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Q3 2024

Quarter Ended Dec 31, 2023

Earnings Release

PDF HTML

Audio

Earnings Webcast

Management Discussion & Analysis

PDF

Financial Statements

PDF

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a strong North American commercial platform. Our product portfolio features leading products that address a variety of diseases, including allergy, dermatology, hematology, oncology and rheumatology.

The leading prescription products are Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, an innovative allergy medication with a unique mode of action; IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery; and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada
T: 877-422-5242